Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM ad hoc committee.
about
Evaluation of the quality of guidelines for myasthenia gravis with the AGREE II instrumentFisher syndrome: clinical features, immunopathogenesis and managementRecent Treatment of Interstitial Lung Disease with Idiopathic Inflammatory MyopathiesAutoimmune neuromuscular disordersTreatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.Influence of immune responses in gene/stem cell therapies for muscular dystrophies.Cryptogenic sensory polyneuropathy.Current and emerging therapies for the treatment of myasthenia gravis.The pathogenesis of multifocal motor neuropathy and an update on current management options.Immune mediated diseases and immune modulation in the neurocritical care unitPlasma exchange versus intravenous immunoglobulin for myasthenia gravis crisis: an acute hospital cost comparison study.Subacute Sensorimotor Polyneuropathy Associated with Autoimmune HepatitisImmunotherapy in Peripheral NeuropathiesDiabetic neuropathy: mechanisms, emerging treatments, and subtypes.Neurological manifestations of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: report from the Consensus Conference on Clinical Practice in chronic graft-versus-host disease.Mechanisms of action of intravenous immunoglobulin in inflammatory muscle disease.Intravenous immunoglobulin therapy in rheumatic diseases.Interstitial Lung Disease in Idiopathic Inflammatory Myopathy.Subcutaneous IgG in neurologic diseases.Chronic inflammatory demyelinating polyradiculoneuropathy and variants: where we are and where we should go.Optimizing IgG therapy in chronic autoimmune neuropathies: a hypothesis driven approach.Intravenous immunoglobulin in neurology--mode of action and clinical efficacy.The antigen-binding fragment of human gamma immunoglobulin prevents amyloid β-peptide folding into β-sheet to form oligomers.Cost-utility analysis of intravenous immunoglobulin for the treatment of steroid-refractory dermatomyositis in Thailand.Economic Evaluation of Intravenous Immunoglobulin plus Corticosteroids for the Treatment of Steroid-Resistant Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Thailand.Novel approaches in the treatment of myositis and myopathies.Hypotension due to Chemotherapy in a Patient with Small Cell Lung Cancer and Lambert-Eaton Myasthenic Syndrome Undergoing Hemodialysis: A First Case Report.Protocol of a dose response trial of IV immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (DRIP study).Maintenance IV immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy.Intravenous immunoglobulin for treatment of neuromuscular disease.Clinical analysis and outcomes of amyotrophic lateral sclerosis with demyelinating polyneuropathy
P2860
Q21131900-E1DE91B6-92C2-4B98-82D5-BE826477D0EBQ22241475-FC0A31E1-4357-46AF-9136-387CC1486039Q26798023-7AC144BB-84E2-4FC7-984C-BE809C1B67A2Q28261039-4E5147EB-C30F-4225-9CAD-9E5A05A9E5EEQ30397454-13A5712E-9011-47BA-8DED-E785E3AC9CC5Q33736192-8EC55CE4-D61C-4ECD-9ECC-D21A355B5C2CQ33878084-ECE4588F-8E45-4FE0-BEC4-0874355773ACQ34879129-71100D1D-2931-4A82-B018-D773CB20057CQ35537340-CD629E5D-A8DA-4538-9DE0-45BFBB0334EEQ35729575-0058F2D8-7F88-425B-AB9B-9DC6DE127F91Q35795404-734E7ECB-0493-4887-AF06-A601F8A660E9Q36460618-CEEB3835-867D-4208-9477-2D7C415581FBQ36484418-003551B4-B2C1-4115-89C6-9BD54DB1F617Q37375109-9F622274-99B8-45D4-9107-8B7799F2500AQ37789530-D85F6392-75DD-4A3B-9A05-CE6710DF5907Q37866685-E9A4BACB-681C-4245-938D-7C8C41BF5975Q37873722-CB71FB95-DE20-4996-AC59-14F1F8DB5641Q37937430-69AE1A82-D601-4D73-A300-28F50FC89524Q38171572-E0B6920A-E0B5-4844-BCB8-1ED543049542Q38194642-40A8A0C5-6A20-40C8-8948-4F9F81829DCDQ38270717-FA512466-2CF7-42E3-B7F0-DD0B961D7C6AQ38308436-5D9F0BF3-F1B7-4C8D-B671-B85709AC95FBQ38806886-DF1D4EAF-5E3A-496C-ADF1-792CCEDE88DDQ39028925-CAF14B40-787E-4BE8-BFC5-8627F71AE681Q39823028-675055AD-7B6D-4AA0-A433-1815F6022079Q41977818-5592D127-5E66-4154-BB15-A686AC6F7316Q42581091-DA34F0FA-7FE8-4CCF-BF3F-409193088E57Q47577354-2FB75A0E-30C7-4FD0-8210-9BFED60FD967Q47584292-680B5FCE-5139-488A-8CFD-A67299E0DD1FQ50133537-CE5CEF37-C541-4CAF-9584-D87C9E12D975Q58271703-CB681AED-BE6D-42ED-8B6B-0DB37F7453DB
P2860
Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM ad hoc committee.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Consensus statement: the use o ...... of the AANEM ad hoc committee.
@en
Consensus statement: the use o ...... of the AANEM ad hoc committee.
@nl
type
label
Consensus statement: the use o ...... of the AANEM ad hoc committee.
@en
Consensus statement: the use o ...... of the AANEM ad hoc committee.
@nl
prefLabel
Consensus statement: the use o ...... of the AANEM ad hoc committee.
@en
Consensus statement: the use o ...... of the AANEM ad hoc committee.
@nl
P2093
P2860
P356
P1433
P1476
Consensus statement: the use o ...... of the AANEM ad hoc committee.
@en
P2093
Adam Quick
Alan Berger
James F Howard
Mark B Bromberg
Normal Latov
Peter D Donofrio
Rup Tandan
Thomas H Brannagan
P2860
P304
P356
10.1002/MUS.21433
P577
2009-11-01T00:00:00Z